UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) ~~January~~March 2821, 2025

Accelerate Diagnostics, Inc.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation)

001-31822		84-1072256
(Commission File Number)		(IRS Employer Identification No.)

3950 South Country Club Road, Suite 470, Tucson, Arizona		85714
(Address of principal executive offices)		(Zip Code)

(520) 365-3100

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of each exchange on which
registered

Common Stock, $0.001 par value per share

AXDX

The Nasdaq Stock Market LLC

(The Nasdaq Capital Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 38.01. ~~Notice~~Other ~~of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing~~Events.

On ~~January~~March 2821, 2025, Accelerate Diagnostics, Inc. (the “Company”) ~~received~~issued ~~written~~a ~~notice~~press ~~(the~~release ~~“Notice”)~~announcing ~~from~~ the ~~Listing~~submission ~~Qualifications Staff (the “Staff”)~~ of ~~the~~its ~~Nasdaq~~Accelerate ~~Stock~~WAVE™ ~~Market,~~system ~~LLC~~and positive ~~(“Nasdaq”)~~blood ~~notifying~~culture ~~the~~gram-negative ~~Company~~test ~~that,~~kit ~~for the last 30 consecutive business days prior~~ to the ~~date~~U.S. ofFood ~~the~~and ~~Notice,~~Drug ~~the~~Administration ~~Company’s Market Value of Listed Securities~~ (~~as defined under Nasdaq rules~~FDA) ~~was below the minimum of $35 million required~~ for ~~continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550~~510(bk)~~(2) (the~~ ~~“MVLS Requirement”)~~clearance. InA ~~accordance~~copy ~~with~~of ~~Nasdaq Listing Rule 5810(c)(3)(C), Nasdaq has provided~~ the ~~Company with 180 calendar~~press ~~days,~~release oris ~~until~~attached ~~July~~hereto ~~28,~~as ~~2025~~Exhibit ~~(the “Compliance Date”), to regain compliance with the MVLS Requirement~~99.1 ~~If,~~and atis ~~any~~incorporated ~~time~~herein ~~before the~~by ~~Compliance~~reference ~~Date, the Market Value of the Company’s common stock (calculated~~ in ~~accordance~~its ~~with Nasdaq rules) closes at $35 million or more for a minimum of ten consecutive business days, Nasdaq will provide written confirmation to the Company and close the matter~~entirety.

~~The~~Item ~~Notice does not result in the delisting of the Company’s common stock from the Nasdaq Capital Market~~9. However, in the event the Company does not regain compliance with the MVLS Requirement prior to the Compliance Date, the Company will receive written notification that its common stock will be subject to delisting01. AtFinancial ~~that~~Statements ~~time,~~and ~~the Company may appeal the Staff’s delisting determination to a Nasdaq Hearing Panel~~Exhibits.

~~The Company is evaluating potential actions to regain compliance with the MVLS Requirement and intends to actively monitor the market value of its common stock~~(d) Exhibits. ~~There can be no assurance that the Company will regain compliance with the MVLS Requirement or otherwise maintain compliance with any of the other Nasdaq listing requirements.~~

Exhibit
Number		Description
99.1		Press Release, dated March 21, 2025
104		Cover Page Interactive Data File (cover page XBRL tags are embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ACCELERATE DIAGNOSTICS, INC.
	(Registrant)
Date: January 29, 2025
Date: March 21, 2025
	/s/ David Patience
	David Patience
	Chief Financial Officer

Filing Compare · Accelerate Diagnostics, Inc